This article has been updated with financial and other details from a Natera regulatory filing.
NEW YORK – Foundation Medicine and Natera said today that they will jointly develop and commercialize personalized circulating tumor DNA monitoring assays for biopharmaceutical and clinical customers who order the FoundationOne CDx test.